NCT04247074 - Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination | Biotech Hunter

Enrollment

413

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

October 2, 2020

Study Completion Date

February 26, 2021

Conditions

Glabellar Frown Lines (GL)Lateral Canthal Lines (LCL)

Interventions

BIOLOGICAL

botulinum toxin neuromodulator

QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

BIOLOGICAL

Placebo

Placebo will be injected into either the LCL, GL, or both the LCL and GL

Trial Locations (12)

Lorenc Aesthetic Plastic Surgery Center, New York

Washington Institute of Dermatologic Laser Surgery, Chevy Chase

Maryland Dermatology, Laser, Skin & Vein Institute, Hunt Valley

Baumann Cosmetic & Research Institute, Inc, Miami

Center for Clinical and Cosmetic Research, Aventura

Elite Aesthetic Research, Cincinnati

Skin Specialists, PC, Omaha

The Westlake Dermatology Clinical Research, Austin

Skin Care & Laser Physicians of Beverly Hills, West Hollywood

Ava MD, Santa Monica

Clinical Testing of Beverly Hills, Encino

Bertucci Medspa, Inc, Woodbridge